RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vascular Biogenics Stock

Vascular Biogenics P/S 2024

Vascular Biogenics P/S

1.81

Ticker

VBLT

ISIN

IL0011327454

WKN

A119YE

As of Sep 29, 2024, Vascular Biogenics's P/S ratio stood at 1.81, a 596.15% change from the 0.26 P/S ratio recorded in the previous year.

The Vascular Biogenics P/S history

Vascular Biogenics Aktienanalyse

What does Vascular Biogenics do?

Vascular Biogenics Ltd (VBL) is a biopharmaceutical company that was founded in 2000. The company is headquartered in Modi'in, Israel and is listed on the NASDAQ under the ticker symbol "VBLT". The history of VBL dates back to the discovery of a protein called Vascular Endothelial Growth Factor-B (VEGF-B) by the company's founder, Professor Moshe Deutsch. VEGF-B is considered a key regulator in blood vessel formation and diseases such as cancer, macular degeneration, and arteriosclerosis. VBL's business model is based on the development and commercialization of novel therapies based on the use of VEGF-B. The company focuses on the development of cancer therapies as well as the treatment of eye diseases and inflammatory diseases. VBL is divided into three divisions: 1. Oncology: In this division, VBL is developing a novel therapy for the treatment of cancer based on a encapsulated version of VEGF-B. This therapy aims to slow tumor growth and activate the patient's immune system to fight the tumor. VBL currently has several ongoing clinical trials that show promising results. 2. Ophthalmology: In this division, VBL is investigating the use of VEGF-B in the treatment of macular degeneration, an eye disease that can lead to vision loss. The company has developed a drug called "VB-421" that has been successfully tested in clinical trials. 3. Inflammatory diseases: VBL is also working on the development of therapies for inflammatory diseases such as rheumatism and colitis. The company also uses the VEGF-B active ingredient for this purpose. In recent years, VBL has already brought several drugs to the market and is continuously working on the development of new therapies. The company collaborates closely with various universities and research institutions. Overall, VBL has achieved promising results in research in recent years and has conducted numerous successful clinical trials. The company focuses on the development of therapies for severe diseases for which there is currently no effective treatment. VBL aims to improve the lives of patients worldwide and make great progress in medicine. Vascular Biogenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Vascular Biogenics's P/S Ratio

Vascular Biogenics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Vascular Biogenics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Vascular Biogenics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Vascular Biogenics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Vascular Biogenics stock

What is the price-to-earnings ratio of Vascular Biogenics?

The price-earnings ratio of Vascular Biogenics is currently 1.81.

How has the price-earnings ratio of Vascular Biogenics changed compared to last year?

The price-to-earnings ratio of Vascular Biogenics has increased by 596.15% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Vascular Biogenics high compared to other companies?

Yes, the price-to-earnings ratio of Vascular Biogenics is high compared to other companies.

How does an increase in the price-earnings ratio of Vascular Biogenics affect the company?

An increase in the price-earnings ratio of Vascular Biogenics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Vascular Biogenics affect the company?

A decrease in the price-earnings ratio of Vascular Biogenics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Vascular Biogenics?

Some factors that influence the price-earnings ratio of Vascular Biogenics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Vascular Biogenics pay?

Over the past 12 months, Vascular Biogenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vascular Biogenics is expected to pay a dividend of 0 USD.

What is the dividend yield of Vascular Biogenics?

The current dividend yield of Vascular Biogenics is .

When does Vascular Biogenics pay dividends?

Vascular Biogenics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vascular Biogenics?

Vascular Biogenics paid dividends every year for the past 0 years.

What is the dividend of Vascular Biogenics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vascular Biogenics located?

Vascular Biogenics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vascular Biogenics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vascular Biogenics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Vascular Biogenics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Vascular Biogenics in the year 2023?

In the year 2023, Vascular Biogenics distributed 0 USD as dividends.

In which currency does Vascular Biogenics pay out the dividend?

The dividends of Vascular Biogenics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vascular Biogenics

Our stock analysis for Vascular Biogenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vascular Biogenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.